Last reviewed · How we verify
PEG-Tα1
PEG-Tα1 is a pegylated thymosin alpha 1 that enhances immune function by promoting T-cell maturation and activation.
PEG-Tα1 is a pegylated thymosin alpha 1 that enhances immune function by promoting T-cell maturation and activation. Used for Chronic hepatitis B, Chronic hepatitis C, Immunodeficiency states.
At a glance
| Generic name | PEG-Tα1 |
|---|---|
| Also known as | Polyethylene Glycol thymosin alpha1, Polyethylene Glycol Thymosin alpha1 |
| Sponsor | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| Drug class | Immunomodulator; pegylated peptide |
| Target | T-cell maturation pathway; thymosin alpha 1 receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology; Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Thymosin alpha 1 (Tα1) is an immunomodulatory peptide that stimulates the maturation and differentiation of T lymphocytes, particularly CD4+ and CD8+ T cells. Pegylation extends the half-life and improves pharmacokinetic properties. The drug enhances both cellular and humoral immune responses, making it useful in conditions requiring immune reconstitution or augmentation.
Approved indications
- Chronic hepatitis B
- Chronic hepatitis C
- Immunodeficiency states
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Headache
Key clinical trials
- Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B (PHASE2)
- Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PEG-Tα1 CI brief — competitive landscape report
- PEG-Tα1 updates RSS · CI watch RSS
- Jiangsu Hansoh Pharmaceutical Co., Ltd. portfolio CI